Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE.
AMIKIN vs BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of mRNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic